ALK-Abello A/S
OTC:AKBLF

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
OTC:AKBLF
Watchlist
Price: 36.1 USD
Market Cap: 7.6B USD

Operating Margin

24.2%
Current
Improving
by 7.5%
vs 3-y average of 16.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
24.2%
=
Operating Income
kr1.5B
/
Revenue
kr6.1B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
24.2%
=
Operating Income
$1.5B
/
Revenue
kr6.1B

Peer Comparison

Country Company Market Cap Operating
Margin
DK
ALK-Abello A/S
CSE:ALK B
49B DKK
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
524.6B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.8B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.2B GBP
Loading...
US
Merck & Co Inc
NYSE:MRK
276.4B USD
Loading...
CH
Novartis AG
SIX:NOVN
219.6B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.2B USD
Loading...
No Stocks Found

Market Distribution

Higher than 78% of companies in Denmark
Percentile
78th
Based on 506 companies
78th percentile
24.2%
Low
-5 981.6% — 1.3%
Typical Range
1.3% — 16.3%
High
16.3% — 423.3%
Distribution Statistics
Denmark
Min -5 981.6%
30th Percentile 1.3%
Median 7.5%
70th Percentile 16.3%
Max 423.3%

ALK-Abello A/S
Glance View

Market Cap
7.6B USD
Industry
Pharmaceuticals

ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.

AKBLF Intrinsic Value
31.89 USD
Overvaluation 12%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
24.2%
=
Operating Income
kr1.5B
/
Revenue
kr6.1B
What is ALK-Abello A/S's current Operating Margin?

The current Operating Margin for ALK-Abello A/S is 24.2%, which is above its 3-year median of 16.7%.

How has Operating Margin changed over time?

Over the last 3 years, ALK-Abello A/S’s Operating Margin has increased from 9.4% to 24.2%. During this period, it reached a low of 9.4% on Sep 30, 2022 and a high of 24.2% on Sep 30, 2025.

Back to Top